NCT00684411View on ClinicalTrials.gov

Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions
T Cell Non-Hodgkin Lymphoma
Interventions
DRUG

Imatinib mesylate

Trial Locations (1)

02115

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Brigham and Women's Hospital

OTHER

collaborator

Novartis

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER